At a glance
ClinicalIndex Comparison RecordN/ACompleted· 450 enrolled
Drug / intervention
Ziprasidonedrug
Likely dose
Ziprasidone 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Dec 24, 2007·Updated Mar 10, 2021
In Brief
An observational study evaluating Ziprasidone for Schizophrenia. Completed, enrolled 450 participants across 20 sites.
Detailed Summary
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesGreece
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedDec 2007
Primary CompletionApr 2009
TodayJul 2026
First PostedDec 24, 2007
Enrollment StartOct 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.5 years ago
Interventions
Ziprasidonedrug
Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection